- Home
- ALX vs OCUL Comparison
ALX vs OCUL Comparison
Compare ALX & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- OCUL
- Stock Information
- Founded
- ALX 1928
- OCUL 2006
- Country
- ALX United States
- OCUL United States
- Employees
- ALX N/A
- OCUL N/A
- Industry
- ALX Real Estate Investment Trusts
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- OCUL Health Care
- Exchange
- ALX Nasdaq
- OCUL Nasdaq
- Market Cap
- ALX 1.0B
- OCUL 957.3M
- IPO Year
- ALX N/A
- OCUL 2014
- Fundamental
- Price
- ALX $229.51
- OCUL $8.11
- Analyst Decision
- ALX Sell
- OCUL Strong Buy
- Analyst Count
- ALX 1
- OCUL 10
- Target Price
- ALX $125.00
- OCUL $16.11
- AVG Volume (30 Days)
- ALX 27.3K
- OCUL 1.8M
- Earning Date
- ALX 05-05-2025
- OCUL 05-05-2025
- Dividend Yield
- ALX 7.87%
- OCUL N/A
- EPS Growth
- ALX N/A
- OCUL N/A
- EPS
- ALX 7.72
- OCUL N/A
- Revenue
- ALX $219,892,000.00
- OCUL $59,647,000.00
- Revenue This Year
- ALX N/A
- OCUL N/A
- Revenue Next Year
- ALX N/A
- OCUL $13.38
- P/E Ratio
- ALX $29.17
- OCUL N/A
- Revenue Growth
- ALX N/A
- OCUL N/A
- 52 Week Low
- ALX $184.76
- OCUL $4.79
- 52 Week High
- ALX $251.63
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- ALX 69.67
- OCUL 57.66
- Support Level
- ALX $221.16
- OCUL $6.86
- Resistance Level
- ALX $224.67
- OCUL $8.21
- Average True Range (ATR)
- ALX 5.04
- OCUL 0.48
- MACD
- ALX 0.81
- OCUL 0.09
- Stochastic Oscillator
- ALX 100.00
- OCUL 88.24
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.